Sector News

Amazon breaks into drug sales with Perrigo's store-brand OTC medications

February 22, 2018
Life sciences

While industry watchers were eagerly anticipating Amazon’s move into prescription drugs, the e-commerce behemoth snuck into over-the-counter sales with help from store brand expert Perrigo.

Amazon rolled out a line of consumer health products, called Basic Care, in August, CNBC reported. The portfolio—consisting of 60 Perrigo-made treatments—sets Amazon up to put the squeeze on retailers of OTC therapies, giving the Dublin drugmaker a boost in the process.

Basic Care doesn’t directly set Amazon up to begin selling prescription drugs, an Amazon spokeswoman told CNBC. But the company last month made its ambitions clearer with the announcement of a venture, in conjunction with JPMorgan and Berkshire Hathaway, to tamp down skyrocketing drug costs.

Amazon already sells branded OTC products on its site, including those from Perrigo’s GoodSense brand, the news service noted. But with Basic Care, Amazon can undercut its competition to reap just a hair in the profit margin column—something it’s got plenty of practice doing.

Of course, just because Amazon’s got the lowest prices doesn’t mean consumers will consistently order the Perrigo brands online instead of running out to a Walgreens or CVS when they need something. Recently departed Perrigo CEO John Hendrickson made that clear to investors last November when he downplayed the potential for a major disruption from a company like Amazon.

“When you want to cure a migraine headache or do something and you go to your pantry and it’s not there, you run to the store and get it. It’s sort of a ‘used as needed,’” he said.

But Perrigo, which is looking for a turnaround under new CEO Uwe Röhrhoff after quite the rocky stretch, will take all the sales it can get. The Dublin drugmaker is in the midst of a major restructuring—which it took on after a run-in with activist investors—and it’s also involved in an industrywide federal investigation into generic drug pricing.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).